The 6th WSPH Task Force on Hemodynamic Definitions and Clinical Classification recently proposed reducing the diagnostic mPAP threshold for pulmonary hypertension.
PAH associated with CHD is linked to significant reductions in survival and quality of life, especially for patients progressing to Eisenmenger syndrome.
Although pulmonary hypertension as a result of interstitial lung disease is linked to significant morbidity and mortality, there is no consensus regarding screening or management of the disease.
Emerging evidence suggests that the extrapulmonary effects of pulmonary arterial hypertension may manifest in the form of vascular dysfunction in systemic circulation, metabolic/endocrine dysfunction, and skeletal and respiratory muscle dysfunction.
Avoiding intubation and mechanical ventilation during subcutaneous pump implantation under local anesthesia and conscious analgosedation was feasible in patients with pulmonary arterial hypertension.
In patients with pulmonary arterial hypertension (PAH) receiving background therapy, treatment with sotatercept led to significant reductions in pulmonary vascular resistance.
The researchers’ goals included determining how postoperative residual pulmonary hypertension was related to longitudinal mortality in patients with severe mitral regurgitation who had mitral valve surgery.
Patients with pulmonary arterial hypertension and iron deficiency in the absence of anemia who received iron supplements did not show significant clinical benefit at 12 weeks.
Since uric acid levels in patients with idiopathic pulmonary arterial hypertension are associated with an impaired clinical and hemodynamic profile, they may serve as a useful noninvasive indicator of disease severity.
In pulmonary arterial hypertension, high plasma levels of hepatic growth factor are associated with the right heart maladaptive phenotype and are incremental to the REVEAL score for the prediction of patient outcomes.
